FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration's approval of Cosentyx (secukinumab) for treating adults with moderate to ... Read More
EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment
The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic arthritis treatment, Cosentyx (secukinumab). This update introduces ... Read More